Skip to content
‹ Back to IndustriesSciences

BE STRATEGIC IN MANUFACTURING AUTOMATION: START WITH THE MANUFACTURING AUTOMATION AUDIT PROGRAM

Manufacturing is a competitive industry. Domestic manufacturers have been competing with overseas manufacturers for decades, which often offer lower cost labor. With competition high and approximately 96.4 percent of U.S. manufacturers qualifying as small businesses, per the U.S. Census Bureau, they are turning toward automation for leaner operations.[1] Automation Increases Productivity Automation delivers higher productivity…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · · Arc Specialties ArticlePromoted Content
Share
BE STRATEGIC IN MANUFACTURING AUTOMATION: START WITH THE MANUFACTURING AUTOMATION AUDIT PROGRAM

Key takeaways

01

Manufacturing is a competitive industry.

02

Domestic manufacturers have been competing with overseas manufacturers for decades, which often offer lower cost labor.

03

With competition high and approximately 96.4 percent of U.S.

Free workspace

Turn your Sciences expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Manufacturing is a competitive industry. Domestic manufacturers have been competing with overseas manufacturers for decades, which often offer lower cost labor. With competition high and approximately 96.4 percent of U.S. manufacturers qualifying as small businesses, per the U.S. Census Bureau, they are turning toward automation for leaner operations.[1]

Automation Increases Productivity

Automation delivers higher productivity and is represented in various applications including robotics. According to Robotic Industries Association (RIA), end-to-end automation in manufacturing can double or even triple throughput.[2] With automation, the equipment can also keep running, giving these manufacturers a competitive edge.

How Will Automation Help You?

Automation is no longer a nice thing to have. It’s imperative. According to a McKinsey study, 478 billion of the 749 billion working hours (64 percent) spent on manufacturing activities globally were automatable with current technology.[3] That’s over half, making it clear that automation is the answer for 21st century manufacturing.

But how will you know what automation application is right for your operations? It can be a challenging scope of work to take on, especially if you’re not experts in automation. ARC Specialties offers manufacturers a Manufacturing Automation Audit Program (MAAP), wherein we evaluate your processes and advise of areas that would be a good fit for automation. We empower manufacturers with automation. All it takes is a consultation and site visit, and you’ll have our recommendations.

Evaluating Automation

It’s not just about embracing automation in your business. It also matters how you integrate it into your workflows. To find these answers, there are nine key automation evaluation points:

  • Production volume
  • Part size
  • Part accuracy
  • Weld acceptance criteria
  • Weld process
  • Joint configuration
  • Material thickness
  • Base material
  • Technical capability of the facility

With these points evaluated, you can proceed with establishing automation to best fit your needs. While so many manufacturers are already using automation, some might not be doing so strategically. Sometimes, businesses rush to take advantage of technology without thinking it through. By partnering with us and allowing us to complete the MAAP, we’ll look at all nine of these points to determine the best set-up for your business.

How You’ll Benefit from MAAP

Go down a strategic path to automation, instead of rushing. In the long-term you’ll be glad you chose to start with a MAAP. From our analysis, key conclusions will be derived about how to employ automation. Those areas include:

  • Machined parts vs. forged parts: machined parts are consistent, whereas forged ones have differences
  • Automation best fits: high volume, low variety areas are best
  • With highly complex processes, more investment is needed in automation, which will impact the return on investment
  • Importance of implementing the technology; even in the best fit scenarios, automation must be engaged to work
  • Determining if the physical facility has the technical capabilities to support automation
  • Easy to use automation is necessary for operators to resolve any concerns with usage

At ARC Specialties, we’re serious about automation and making it work for your specific application. We aren’t keen to sell you something you don’t need. We are focused on being a partner to manufacturers as they embrace automation. Contact us today to talk more about MAAP and how we can help you automate.

Read more at arcspecialties.com

[1] https://www.census.gov/foreign-trade/Press-Release/edb/2015/edbrel.pdf

[2] https://www.robotics.org/blog-article.cfm/Benefits-of-Manufacturing-Automation/25

[3] https://www.mckinsey.com/business-functions/operations/our-insights/human-plus-machine-a-new-era-of-automation-in-manufacturing

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Book DemoSee how it works15 minutes, straight to a calendar.

About the author

S
Sciences
B2B Weekly

The week in Sciences, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Sciences Insights

Antibody developability checks are moving into discovery instead of waiting for development

Antibody developability checks are moving into discovery instead of waiting for development

Maria Gonzalez-Pajuelo of FairJourney Bio says the order in antibody discovery is changing: developability has become a much more important consideration during discovery, rather than an issue left until later-stage development. The goal, she says, is that what comes out of discovery is something CMC can take forward easily.

  • 01Discovery-stage developability screens can rank many antibodies tested once or twice and may reduce surprises later in development, while development still focuses on several lots of a single antibody and answers different questions.

Oct 1, 2026

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

Caraballo expects AI across all five tracks at ISPE’s 2026 Annual Meeting

ISPE’s 2026 Annual Meeting and Expo in Washington, DC organizes its program around five tracks running from discovery to governance, with international program committee chair Connie Langer of Pfizer Global Supply and executive chair Jose Caraballo of JCO Global Advisory LLC describing how the tracks connect—and why AI is treated as a cross-cutting topic rather than a standalone track. Deloitte’s December 2025 survey of 280 executives frames the mood the program is built for.

  • 01ISPE’s 2026 Annual Meeting has no dedicated AI track; executive chair Jose Caraballo expects AI presentations across all five tracks, from discovery to governance.
  • 02Deloitte’s December 2025 survey of 280 biopharma and medtech C-suite executives found more than 75% confident in their own outlook but only 41% optimistic about the global economy, a mood the story says the ISPE chairs are programming for.
  • 03A staffing firm reports life sciences job openings falling even as digital fluency becomes a required skill, so the upskilling burden lands on the people already employed, which is where the mandatory, university-partnered AI training Connie Langer describes at her company sits.

Sep 30, 2026

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site fits the tumor model to the therapy, not the reverse

Crown Bioscience's San Diego site designs preclinical tumor models to match specific therapies and delivery routes, rather than forcing treatments into standard study designs. It combines custom surgical procedures, cell line-derived xenografts, patient-derived xenografts (including post-treatment models), and biomarker capabilities to generate translational data that can help sponsors decide whether to advance a program.

  • 01Orthotopic brain tumor implantation using tagged models lets researchers track tumor growth in the original organ, aligning the model and delivery route with how therapies are intended to be tested.
  • 02Patient-derived xenografts developed from tumors after prior treatment may better reflect progressed disease, helping teams study therapies aimed at patients whose cancer has advanced after earlier treatment.
  • 03Combining biomarker analysis of preclinical model samples with clinical sample testing at one site could make it easier to connect what is measured in animals with what is later measured in patients.

Sep 30, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512